Immuneering Corp income statement

In fiscal 2023, Immuneering Corp reported revenue of $0, down 100.0% on the year before and net income of −$53.5m, or −$1.88 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Immuneering Corp: income statement, annual
Fiscal year	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023
Revenue	2	2	0	0
Cost of revenue	1	1	0	0
Gross profit	1	1	0	0
Research and development	15	27	36	42
General and administrative	3	8	16	17
Operating income	−17	−34	−52	−58
Income before tax	−17	−34	−51	—
Income tax	—	−0	—	—
Net income	−17	−34	−51	−53
Diluted EPS	−$1.72	−$1.23	−$1.91	−$1.88
Diluted shares (average)	10m	27m	26m	28m
EBITDA	−17	−34	−51	−58

US$ millions unless shown otherwise. Fiscal quarters.

Immuneering Corp: income statement, quarterly
Quarter	2022 Q1Mar 2022	2022 Q2Jun 2022	2022 Q3Sept 2022	2022 Q4Dec 2022	2023 Q1Mar 2023	2023 Q2Jun 2023	2023 Q3Sept 2023	2023 Q4Dec 2023
Revenue	0	0	0	0	0	0	0	0
Cost of revenue	0	0	0	0	0	0	0	0
Gross profit	0	0	0	0	0	0	0	0
Research and development	9	8	9	10	10	9	10	12
General and administrative	4	4	4	4	4	4	4	4
Operating income	−13	−12	−13	−14	−15	−14	−14	−16
Net income	−13	−12	−13	−13	−14	−12	−13	−15
Diluted EPS	−$0.49	−$0.44	−$0.49	−$0.50	−$0.51	−$0.43	−$0.43	−$0.52
EBITDA	−13	−12	−13	−14	−15	−13	−14	−16

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Immuneering Corp's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Immuneering Corp.